Jonathan Toledo, Pablo Aníbal Perez, Mical Zanetti, Graciela Díaz-Torga, Jorge Humberto Mukdsi, Silvina Gutierrez
The Journal of endocrinology 2024 Jan 01Due to the current limited knowledge about the role of filamin A (FLNA) in pituitary tumour progression, we aimed to analyse FLNA expression levels and its impact on aggressive markers of pituitary neuroendocrine tumours (PitNETs), using an integrative approach of in vivo and in vitro models and human samples. An increase in the expression levels of FLNA was observed in the advanced tumoural stages of the hyperplastic adenomatous pituitary model, concomitant with a decrease in cell proliferation and with a modification in the subcellular localisation of this protein. Similarly, overexpression of FLNA in the somatolactotropic GH3 cell line induced a decrease in the cell proliferation, promoted a migratory phenotype, increased invasion activity, and decreased the prolactin secretion. Cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4) expression increased in both models in correlation with the increase observed in FLNA levels. When human tissues were analysed a significant increase of FLNA was observed in PitNETs compared to normal pituitary gland, with heterogeneous intracellular localisation. Higher levels of FLNA expression were observed in tumours with invasive characteristics. These results underline the crucial roles of FLNA as a modulator of pathological markers and as a potential prognostic marker in pituitary tumours.
Jonathan Toledo, Pablo Aníbal Perez, Mical Zanetti, Graciela Díaz-Torga, Jorge Humberto Mukdsi, Silvina Gutierrez. FLNA expression modulates pathological markers of pituitary neuroendocrine tumours. The Journal of endocrinology. 2024 Jan 01;260(1)
PMID: 37855268
View Full Text